We fund the development and application of OoC technology across our research funding and CRACK IT innovation programmes, and encourage applications in this space. To date we have committed £10.2M funding, which has led to the development of OoC models for assessing kidney and CNS toxicities and ovarian cancer research. Below, you can find out more about the OoC research we have funded.
We fund new model development through our Project grants and early career awards (PhD Studentships and Training Fellowships). Our Skills and Knowledge Transfer grants support the adoption of established 3Rs technologies through funding collaborations between model developers and end-users.
Our CRACK IT programme champions innovation in the 3Rs, turning great ideas into products and services.
- If you are an end-user, you may be interested in submitting an idea for a CRACK IT Challenge through our annual open call (e.g. a call for a new product or technology targeted to your needs). Visit the Sponsor a Challenge page on our Innovation Platform website to find out more.
- If you are a technology developer looking to identify new partners and customers to further develop, validate and use your OoC technology then you may be interested in showcasing your technology through the technology partnering platform konfer. Please visit the Technology Partnering page on the Innovation Platform website for further information.
OoC research we have funded
Training fellowships and studentships:
- Developing microfluidic systems for high-throughput studies of functional neuronal networks
- An ovarian cancer model on a chip
- Microfluidic networks: an in vitro 3D culture system for the investigation of neuron-glial interactions in neurodegeneration
- Developing an organ on a chip model to test the therapeutic efficacy of adhirons in breast cancer
- Modeling central and peripheral nervous system connectivity using compartmentalised microfluidic systems
- Training in hIPSC differentiation protocols to generate motor neuron-muscle cultures to replace rat models in study of mitochondria on axon physiology
- Recreating thrombosis models using tissue-engineered arterial constructs: A novel method to reduce and replace mice used in platelet research
- Advanced in vitro and in silico models to predict and prevent deep venous thrombosis
- A 3Rs approach to tumour metastasis: investigating the role of cancer stem cells in metastasis using an in vitro microfluidic model
- Development and characterization of a novel endothelialized in vitro model of human atherothrombosis
- 'MacuSIM': A microfluidic, in vitro model of the outer retina as an experimental platform for macular disease and therapeutic trials
- Drug risk assessment and repurposing using biomimetic chromatography and body-on-chip technology
- A 3Rs approach to investigate the feto-maternal interface: visualisation of pathogen and antibody in a 3D in vitro human placental model
- In vitro multi-chamber systems for studying neural degeneration processes
- Modelling the human asthmatic airway by tissue engineering
- A compartmentalised chamber for the in vitro study and manipulation of axon degeneration
- Engineering fully functional, integrated skeletal muscle
- Replacement of animal models for tumour biology with a multifunctional microfluidic-based approach
- Development of an in vitro model of "pain"
- Validation of an in vitro humanised 3D haematopoietic system to investigate haematological malignancies
Further funded research projects:
- Optimising liver equivalents to model liver fibrosis
- Optimisation of a flow-based human in vitro blood-brain barrier model to replace animal models for studying immunopathogenesis of viral brain infections
- Translating microvascularised chips of a nephrotoxicity model
- Utilising tissue-on-a-chip technology as an ex vivo model of breast cancer metastatic colonisation
- Fully humanised 3D vascular perfused model for breast cancer modelling and therapeutic screening
- Replacing in vivo models with the Quasi vivo system to investigate metastatic site priming by tumour cells
- Determining the efficacy and safety of cancer chemotherapeutics for cholangiocarcinoma (CCA) using Human Precision Cut Tissue Slices (hPCTS)